

Fast Atom Bombardment Mass Spectra of *N*-Phosphorylated Peptide Analogs

Hua Fu,¹ Zhaolong Li,¹ Jingzun Wang² and Yufen Zhao^{1*}

¹ Bioorganic Phosphorus Chemistry Laboratory, Department of Chemistry, Tsinghua University, Beijing 100084, China

² Beijing Institute of Microchemistry, Beijing 100091, China

A series of *N*-(*N*-alkyl)- and *N*-(*O*-alkyl)phosphopeptide analogs were determined by positive and negative ion fast atom bombardment mass spectrometry and their fragmentation pathways were investigated. Their mass spectra gave abundant $[\text{MH} - \text{NH}_2\text{R}']^+$, $[\text{MH} - \text{HOR}']^+$, $[\text{MH} - \text{H}_2\text{O}]^+$ or $[\text{M} - \text{H} - \text{NH}_2\text{R}']^-$, $[\text{M} - \text{H} - \text{HOR}']^-$ ions, which contained pentavalent tricoordinate phosphorus ions through the loss of amine or water. In the positive ion mass spectra, $^+\text{NH}_3\text{R}'$ and $^+\text{NH}_3\text{CHRCONHR}'$ were found, while $[\text{MH} - \text{NH}_2\text{CHRCONHR}']^+$ was suppressed. In the negative ion mass spectra, the pseudomolecular ion $[\text{M} - \text{H}]^-$ was the base peak, and almost all the fragment ions contained a phosphoryl group. © 1997 by John Wiley & Sons, Ltd.

J. Mass Spectrom. 32, 813–819 (1997)

No. of Figures: 8 No. of Tables: 4 No. of Refs: 12

KEYWORDS: fast atom bombardment mass spectrometry; *N*-phosphorylated peptide analogs

INTRODUCTION

N-Phosphoamino acids show many interesting bioorganic chemical reactions under mild conditions.^{1–6} For example, *N*-phosphoamino acids can self-activate to give peptides and esters, together with the phosphoryl ester-exchanged and phosphoryl group migration products. A mechanism involving a pentacoordinate intramolecular phosphoric–carboxylic mixed anhydride intermediate was suggested, which was proved by the synthesis of a series of pentacoordinate phosphoric–carboxylic mixed anhydrides.⁷ Previously, some *N*-dialkyloxyphosphoamino acids and -peptides were studied by positive and negative ion fast atom bombardment mass spectrometry (FABMS),^{8–11} and their fragmentation patterns were summarized. It is interesting that by introduction of the *N*-dialkyloxyphosphoryl group into amino acids, the sensitivity of their positive ion FAB mass spectra could be improved by factors of 4–29. The chemical noise derived from the liquid matrix was greatly reduced.⁸ For *N*-phosphopeptides, their positive ion FAB mass spectra showed a novel cleavage pattern in which only the *N*-phosphoryl fragment ions gave intense peaks, while their *C*-terminal series ion and the glycerol matrix

were suppressed.^{10,11} All these advantages make it convenient to identify the structure of amino acids by FABMS and provide a promising approach for molecular mass determination and sequence analysis for peptides. In this work, a series of *N*-(*N*-alkyl)- and *N*-(*O*-alkyl)phosphorylated peptide analogs were studied by positive and negative ion FABMS and their mass spectral fragmentation pathways were elucidated.

EXPERIMENTAL

Preparation of samples

N-(*N*-Alkyl)phosphorylated peptide analogs 2a₁–h₁. Under a nitrogen atmosphere, benzylamine or pentylamine was added to a fresh benzene solution of pentacoordinate phosphoric–carboxylic mixed anhydrides 1a–h⁷ at 25 °C and after hydrolysis each product was isolated by high-performance liquid chromatography (HPLC) to give 2a₁–h₁ and 2a₂–h₂.

N-(*O*-Alkyl)phosphorylated peptide analogs 3a–h. Each of the *N*-(*N*-benzyl)phosphorylated peptide analogs 2a–h was reacted with an alcohol solution to give the corresponding *N*-(*O*-alkyl)phosphorylated peptide analogs 3a–h, which were purified by HPLC.

Their structures were characterized by ¹H, ¹³C and ³¹P NMR spectroscopy. For example, the ¹H, ¹³C and ³¹P NMR data for 2d₁ and 3d₁ are listed as examples. The ¹H and ¹³C NMR spectra were recorded on a


* Correspondence to: Y. Zhao, Bioorganic Phosphorus Chemistry Laboratory, Department of Chemistry, Tsinghua University, Beijing 100084, China.

Contract grant sponsor: National Natural Science Foundation of China.

Contract grant sponsor: National Science and Technology Committee of China.

Contract grant sponsor: Chinese National Ministry of Education.

Contract grant sponsor: Tsinghua University



Bruker AM 500 spectrometer at 500 MHz and the ^{31}P NMR spectra on a Bruker AM 200 spectrometer at 200 MHz, with D_2O as solvent.

For *N*-(*N*-benzyl)phospholeucine *N*-benzylamide (**2d₁**): ^1H NMR, δ 0.94, 1.02 (q, 6H, 4,5- CH_3), 1.76 (m, 1H, 3-CH), 2.42 (m, 2H, 2- CH_2), 3.87 (m, 1H, 1-CH, $^3J_{\text{P,H}} = 9.1$ Hz), 4.24 (s, 2H, 7- CH_2), 4.57 (d, 2H, 9- CH_2 , $^3J_{\text{P,H}} = 6.9$ Hz), 7.43–7.71 (m, 10H, 8,10-Ph); ^{13}C NMR, δ 21.7 23.1 (4,5- CH_3), 25.20 (3-CH), 42.86 (2-


CH_2), 44.23, 44.61 (7,9- CH_2 , $^2J_{\text{P,C}} = 7.2$ Hz), 53.36 (1-CH, $^2J_{\text{P,C}} = 7.4$ Hz), 128.21, 128.26, 128.54, 129.17, 129.94, 130.15, 131.79, 132.33, 133.57, 134.37, 135.33, 136.77 (8,10-Ph), 166.23 (6-CO); ^{31}P NMR, δ 10.8.

For *N*-(*O*-methyl)phospholeucine *N*-benzylamide (**3d₁**): ^1H NMR, δ 0.91, 1.02 (q, 6H, 4,5- CH_3), 1.73 (m, 1H, 3-CH), 2.43 (m, 2H, 2- CH_2), 3.63 (s, 2H, 9- CH_2 , $^3J_{\text{P,H}} = 8.2$ Hz), 3.87 (m, 1H, 1-CH, $^3J_{\text{P,H}} = 8.4$ Hz), 4.56 (s, 7- CH_2), 7.44–7.50 (m, 5H, 8-Ph); ^{13}C NMR, δ

Table 1. Positive ion FAB/MS main fragment ions for *N*-(*N*-alkyl)phosphorylated peptide analogs **2a–h** [relative intensity (%) in parentheses]^a

2	MH^+	$[\text{MH} - \text{H}_2\text{O}]^+$	$[\text{MH} - \text{NH}_2\text{R}']^+$	$[\text{MH} - \text{HCONHR}']^+$	$[\text{X} + \text{H}]^+$	$^+\text{NH}_3\text{R}'$
a₁	334 (15)	316 (13)	227 (100)	199 (14)	165 (16)	108 (21)
a₂	294 (13)	276 (12)	207 (100)	179 (15)	145 (12)	88 (16)
b₁	348 (16)	330 (14)	241 (100)	213 (16)	179 (18)	108 (23)
b₂	308 (13)	290 (12)	221 (100)	193 (14)	159 (15)	88 (26)
c₁	376 (14)	358 (8)	269 (100)	241 (12)	207 (18)	108 (20)
c₂	336 (12)	318 (7)	249 (100)	221 (5)	187 (34)	88 (12)
d₁	390 (14)	372 (16)	283 (100)	255 (10)	221 (16)	108 (10)
d₂	350 (12)	332 (10)	263 (100)	235 (5)	201 (10)	88 (8)
e₁	408 (18)	390 (16)	301 (100)	273 (8)	239 (21)	108 (23)
e₂	368 (14)	350 (15)	281 (100)	253 (8)	219 (21)	88 (27)
f₁	424 (19)	406 (19)	317 (100)	289 (12)	255 (20)	108 (30)
f₂	384 (18)	366 (20)	297 (100)	269 (11)	235 (22)	88 (24)
g₁	364 (10)	346 (18)	257 (100)	229 (8)	195 (18)	108 (19)
g₂	324 (8)	306 (17)	237 (100)	209 (9)	175 (16)	88 (23)
h₁	414 (28)	396 (3)	307 (100)	279 (4)	245 (30)	108 (44)
h₂	374 (15)	356 (3)	287 (100)	259 (3)	225 (42)	88 (32)

^a X = $\text{H}_2\text{NCHRCONHCH}_2\text{Ph}$; R' = CH_2Ph (subscript 1) and C_6H_{11} (2).



Scheme 1. Positive ion FAB mass spectral fragmentation pathways for *N*-(*N*-alkyl)phosphorylated peptide analogs **2a-h**.

21.7, 23.1 (4,5-CH₃), 25.18 (3-CH), 42.86 (2-CH₂), 44.32 (7-CH₂), 52.82 (9-CH₃, ²J_{P,C} = 6.3 Hz), 53.85 (1-CH, ²J_{P,C} = 7.5 Hz), 127.57, 128.16, 128.78, 129.18, 129.45, 129.78, (8-Ph), 167.18 (6-CO); ³¹P NMR, δ 8.2.

Mass spectrometric conditions

Positive and negative ion FAB mass spectra were recorded on a Finnigan MAT 90 double-focusing

instrument (Finnigan MAT, Bremen, Germany) of BE geometry. The standard gun was operated at current 5 mA and energy 20 keV using the Cs⁺ ion as a bombarding ion. All the samples were measured in a glycerol matrix. Some ions were analyzed using the manufacturer's software for *B/E* linked scan in the first field-free region of the instrument. The scan rate was 10 s per decade, and conventional resolution of the instrument was adjusted to 1000 (10% valley definition). The scan mass range was from 50 to 800 u.

RESULTS AND DISCUSSION

Positive ion FAB mass spectra of *N*-(*N*-alkyl)- and *N*-(*O*-alkyl)phosphorylated peptide analogs **2a-h** and **3a-h**

According to Table 1, for each of the *N*-(*N*-alkyl)phosphorylated peptide analogs **2a-h**, all the protonated molecular ion MH⁺ was observed together with a peak due to the loss one molecule of water, [MH - H₂O]⁺;




Figure 1. Positive ion FAB mass spectrum of *N*-(*N*-benzyl)phospholeucine *N*-benzylamide (**2d₁**).





Figure 2. Positive ion FAB mass spectrum of *N*-(*O*-methyl)phospholeucine *N*-benzylamide (**3d₁**).



Scheme 2. Positive ion FAB mass spectral fragmentation pathways for *N*-(*O*-alkyl)phosphoamino acid *N*-benzylamides **3a–h**.

the ions $[MH - NH_2R']^+$ showed the base peaks as deduced by either the cleavage of an amide bond, $-\text{CO}-\text{NH}-$ or by loss of one molecule of amine, $-\text{P}(\text{O})-\text{NH}-$ bonds. Other ions, $[MH - \text{CONHR}']^+$, $^+\text{NH}_3\text{R}'$ and $[\text{H}_2\text{NCHRCONHR}' + \text{H}]^+$, were observed, similarly to the fragmentation behaviour of a peptide.¹² Their general fragmentation pathways are shown in Scheme 1. For example, the spectrum of *N*-(*N*-benzyl)phospholeucine *N*-benzylamide (**2d**₁) is shown in Fig. 1. The protonated molecular ion at m/z 390 together with the water-loss ion at m/z 372 were observed. The base peak at m/z 283 was due to the loss of a benzylamine molecule. Ions $^+\text{NH}_3\text{R}'$ at m/z 108 and $^+\text{NH}_3\text{CHRCONHR}'$ at m/z 221 were also observed.

When the *N*-alkyl group on phosphorus in compounds **2a–h** was displaced by *O*-alkyl to give **3a–h**, their mass spectra showed some similar fragmentation pathways, as shown in Table 2, Fig. 2 and Scheme 2, with the difference that $[MH - \text{H}_2\text{O}]^+$, $[MH - \text{NH}_2\text{R}']^+$ were suppressed. It has been reported previously that *N*-(*O*-dialkyl)phosphoamino acids and -peptides usually exhibit the peaks due to two successive alkene losses,^{8–10} while the *N*-(*O*-alkyl)phosphorylated peptide analogs **3a–h**, containing a hydroxyl on phosphorus, could lose an alcohol to form pentavalent tricoordinate phosphorus ions.

Negative ion FAB mass spectra of *N*-(*N*-alkyl)- and *N*-(*O*-alkyl)phosphorylated peptide analogs

The negative ion FAB mass spectral data for *N*-(*N*-alkyl)phosphorylated peptide analogs are given in Table 3. It can be seen that all pseudomolecular ions $[M - \text{H}]^-$ for **2a–h** were the base peaks, which were correlated with their structures due to a strong acidic hydroxyl group on the phosphorus. The abundant ions $[M - \text{H} - \text{NH}_2\text{R}']^-$ and $[M - \text{H} - \text{NH}_2\text{CHRCONHR}']^-$ were also observed. For example, for *N*-(*N*-alkyl)phospholeucine *N*-benzylamide (**2d**₁) (Fig. 3), the deprotonated molecular ion at m/z 388 showed the base peak and, the peaks at m/z 281 and 168 were due to $[M - \text{H} - \text{NH}_2\text{R}']^-$ and $[M - \text{H} - \text{NH}_2\text{CHRCONHR}']^-$. Their fragmentation pathways are shown in Scheme 3. It is worth noting that almost all ions contained a phosphoryl group.

For all the *N*-(*O*-alkyl)phosphorylated peptide analogs **3d–h**, their negative FAB mass spectra showed

Table 2. Positive ion FABMS main fragment ions for *N*-(*O*-alkyl)phosphoamino acid *N*-benzylamides **3a–h** [relative intensity (%) in parentheses]^a

3	MH ⁺	[MH - R''OH] ⁺	[X + H] ⁺	[MH - HCONHCH ₂ Ph] ⁺	⁺ NH ₃ CH ₂ Ph
a ₁	259 (62)	227 (36)	165 (23)	124 (12)	108 (47)
a ₂	273 (56)	227 (32)	165 (31)	138 (14)	108 (53)
a ₃	287 (45)	227 (28)	165 (18)	152 (8)	108 (47)
b ₁	273 (68)	241 (31)	179 (32)	138 (6)	108 (37)
b ₂	287 (57)	241 (27)	179 (27)	152 (11)	108 (33)
b ₃	301 (58)	241 (30)	179 (21)	166 (5)	108 (31)
c ₁	301 (70)	269 (42)	207 (31)	166 (9)	108 (47)
c ₂	315 (56)	269 (26)	207 (26)	180 (13)	108 (32)
c ₃	329 (28)	269 (31)	207 (18)	194 (16)	108 (46)
d ₁	315 (74)	283 (30)	221 (28)	180 (20)	108 (35)
d ₂	329 (69)	283 (8)	221 (56)	194 (28)	108 (48)
d ₃	343 (53)	283 (18)	221 (35)	208 (19)	108 (49)
e ₁	333 (45)	301 (18)	239 (22)	198 (23)	108 (40)
e ₂	357 (53)	301 (24)	239 (12)	212 (31)	108 (37)
e ₃	371 (35)	301 (12)	239 (20)	226 (14)	108 (38)
f ₁	349 (38)	317 (16)	255 (13)	214 (12)	108 (41)
f ₂	363 (44)	217 (25)	255 (16)	228 (14)	108 (45)
f ₃	377 (28)	317 (11)	255 (15)	242 (15)	108 (53)
g ₁	389 (22)	257 (8)	195 (12)	154 (8)	108 (41)
g ₂	303 (32)	257 (16)	195 (5)	168 (6)	108 (45)
g ₃	317 (16)	257 (6)	195 (8)	182 (9)	108 (21)
h ₁	339 (18)	307 (12)	245 (42)	204 (15)	108 (32)
h ₂	353 (26)	307 (16)	245 (32)	218 (18)	108 (36)
h ₃	367 (18)	307 (14)	245 (38)	232 (16)	108 (42)

^a Tropilium ion at m/z 91 is the base peak. X = H₂NCHRCONHCH₂Ph; R'' = CH₃ (subscript 1), C₂H₅ (2) and CH(CH₃)₂ (3).

Table 3. Negative ion FABMS main fragment ions for *N*-(*N*-alkyl)phosphorylated peptide analogs 2a-h [relative intensity (%) in parentheses]^a

2	[M-H] ⁻	[M-H-NH ₂ R'] ⁻	[M-H-HCONHR'] ⁻	[M-H-NH ₂ CH RCONHR'] ⁻
a ₁	332 (100)	225 (56)	197 (8)	168 (10)
a ₂	292 (100)	205 (52)	177 (6)	148 (11)
b ₁	346 (100)	239 (48)	211 (10)	168 (12)
b ₂	306 (100)	219 (52)	191 (7)	148 (10)
c ₁	374 (100)	267 (63)	239 (5)	168 (11)
c ₂	334 (100)	247 (88)	219 (7)	148 (11)
d ₁	388 (100)	281 (44)	253 (5)	168 (12)
d ₂	348 (100)	261 (44)	233 (8)	148 (16)
e ₁	406 (100)	299 (51)	271 (8)	168 (15)
e ₂	366 (100)	279 (49)	251 (6)	148 (14)
f ₁	422 (100)	315 (54)	287 (10)	168 (14)
f ₂	382 (100)	295 (43)	267 (9)	148 (12)
g ₁	362 (100)	255 (32)	227 (7)	168 (15)
g ₂	322 (100)	235 (28)	207 (5)	148 (11)
h ₁	412 (100)	305 (66)	277 (13)	168 (20)
h ₂	372 (100)	285 (63)	257 (12)	148 (18)

^a R' = CH₂Ph (subscript 1) and C₆H₁₁ (2).

similar fragmentation behaviour to the above (Table 4, Scheme 4). For example *N*-(*O*-alkyl)phospholeucine *N*-benzylamide (3d₁) (Fig. 4) showed an abundant deprotonated molecular ion at *m/z* 313. In addition, the ion at *m/z* 281 came from loss of an alcohol. Abundant ions corresponding to PO₂⁻ at *m/z* 63 and PO₃⁻ at *m/z* 79 were also found, while ions [M-H





Scheme 3. Negative ion FAB mass spectral fragmentation pathways for *N*-(*N*-alkyl)phosphorylated peptide analogs 2a-h.

Scheme 4. Negative ion FAB mass spectral fragmentation pathways for *N*-(*O*-alkyl)phosphoamino acid *N*-benzylamides.

Figure 3. Negative ion FAB mass spectrum of *N*-(*N*-benzyl)phospholeucine *N*-benzylamide (2d₁).

Table 4. Negative ion FABMS main fragment ions for *N*-(*O*-alkyl)phosphoamino acid *N*-benzylamides 3a–h [relative intensity (%) in parentheses]^a

3	[M – H] [–]	[M – H – NH ₂ R'] [–]	[M – H – HCONHR'] [–]	PO ₃ [–]	PO ₂ [–]
a ₁	257 (100)	225 (55)	122 (5)	79 (64)	63 (22)
a ₂	271 (42)	225 (34)	136 (8)	79 (100)	63 (26)
a ₃	285 (23)	225 (21)	150 (12)	79 (100)	63 (21)
b ₁	271 (100)	239 (42)	136 (6)	79 (57)	63 (20)
b ₂	285 (35)	239 (34)	150 (11)	79 (100)	63 (31)
b ₃	299 (31)	239 (21)	164 (15)	79 (100)	63 (27)
c ₁	299 (100)	267 (39)	164 (7)	79 (61)	63 (23)
c ₂	313 (47)	267 (30)	178 (4)	79 (100)	63 (18)
c ₃	327 (40)	267 (21)	192 (9)	79 (100)	63 (16)
d ₁	313 (100)	281 (34)	178 (8)	79 (60)	63 (25)
d ₂	327 (32)	281 (20)	192 (5)	79 (100)	63 (24)
d ₃	341 (10)	281 (9)	206 (1)	79 (100)	63 (15)
e ₁	331 (100)	299 (51)	196 (4)	79 (65)	63 (24)
e ₂	345 (51)	299 (35)	210 (7)	79 (100)	63 (20)
e ₃	359 (28)	299 (19)	224 (8)	79 (100)	63 (13)
f ₁	347 (100)	315 (53)	212 (11)	79 (54)	63 (21)
f ₂	361 (41)	315 (32)	226 (10)	79 (100)	63 (21)
f ₃	375 (26)	315 (27)	240 (7)	79 (100)	63 (12)
g ₁	287 (100)	255 (41)	152 (8)	79 (61)	63 (31)
g ₂	301 (65)	255 (32)	166 (6)	79 (100)	63 (35)
g ₃	315 (39)	255 (27)	180 (4)	79 (100)	63 (32)
h ₁	337 (100)	305 (48)	202 (5)	79 (58)	63 (18)
h ₂	351 (52)	305 (29)	216 (7)	79 (100)	63 (23)
h ₃	365 (37)	305 (33)	230 (4)	79 (100)	63 (28)

^a R' = CH₃ (subscript 1), C₂H₅ (2) and CH(CH₃)₂ (3).

– NH₂CHRCONHR'][–] at *m/z* 95 and [M – H – NH₂R'][–] at *m/z* 106 were suppressed.

CONCLUSION

The positive and negative ion FAB mass spectra of *N*-phosphorylated peptide analogs provided abundant structural information and could complement each other. In the positive ion mass spectra, the abundance of the protonated molecular ion was lower, whereas abundant [MH – NH₂R']⁺ could be observed and [MH – H₂O]⁺, ⁺NH₃R' and ⁺NH₃CHRCONHR'

were also found. In the negative ion mass spectra, almost all of the deprotonated molecular ions were base peaks, and fragment ions contained a phosphoryl group. FABMS has the advantages of low discrimination and good detection limits for the analysis of *N*-phosphorylated peptide analogs.

Acknowledgements

The authors acknowledge financial support from the National Natural Science Foundation of China, the National Science and Technology Committee of China, the Chinese National Ministry of Education and Tsinghua University.




Figure 4. Negative ion FAB mass spectrum of *N*-(*O*-methyl)phospholeucine *N*-benzylamide (3d₁).

REFERENCES

1. J. N. Zeng, C. B. Xue, Q. W. Chen and Y. F. Zhao, *Bioorg. Chem.* **17**, 434 (1989).
2. G. J. Ji, C. B. Xue, J. N. Zeng, L. P. Li, W. G. Chai and Y. F. Zhao, *Synthesis* **6**, 444 (1988).
3. X. B. Ma and Y. F. Zhao, *J. Org. Chem.* **29**, 1145 (1988).
4. C. B. Xue, Y. W. Yin and Y. F. Zhao, *Tetrahedron Lett.* **29**, 1145 (1988).
5. C. B. Xue and Y. F. Zhao, *J. Chem. Soc., Perkin Trans. 2*, 431 (1990).
6. Y. M. Li and Y. F. Zhao, *Int. J. Pept. Protein Res.* **38**, 1 (1992).
7. Q. Wang, Y. F. Zhao, F. L. An, Y. Q. Mao and J. Z. Wang, *Sci. China, Ser. B* **25**, 684 (1995).
8. W. G. Chai, L. Yan, G. H. Wang, X. Y. Liang, Y. F. Zhao and G. J. Ji, *Biomed. Mass Spectrom.* **14**, 331 (1987).
9. X. B. Xue, Y. W. Yin, X. Yu and Y. F. Zhao, *Org. Mass Spectrom.* **24**, 253 (1989).
10. Y. F. Zhao, D. Q. Zhang, C. B. Xue, J. N. Zeng and G. J. Ji, *Org. Mass Spectrom.* **26**, 510 (1991).
11. X. B. Ma and Y. F. Zhao, *Biol. Mass Spectrom.* **20**, 498 (1991).
12. S. Seki, H. Kambara and H. Naoki, *Org. Mass Spectrom.* **20**, 18 (1985).